Karyopharm Therapeutics Inc. (KPTI) EPS Estimated At $-0.58; Globant S.A. (GLOB) Covered By 6 Bullish Analysts Last Week

February 20, 2018 - By Hazel Jackson

Among 10 analysts covering Globant SA (NYSE:GLOB), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. Globant SA had 25 analyst reports since July 27, 2015 according to SRatingsIntel. SunTrust initiated Globant S.A. (NYSE:GLOB) on Monday, December 21 with “Buy” rating. The stock of Globant S.A. (NYSE:GLOB) earned “Hold” rating by SunTrust on Thursday, July 27. The rating was initiated by Sterne Agee CRT with “Buy” on Thursday, December 17. The stock of Globant S.A. (NYSE:GLOB) earned “Outperform” rating by Wedbush on Friday, September 9. The stock of Globant S.A. (NYSE:GLOB) has “Sector Weight” rating given on Friday, July 7 by KeyBanc Capital Markets. The firm has “Buy” rating given on Thursday, August 11 by Citigroup. The firm earned “Hold” rating on Thursday, November 16 by SunTrust. Pacific Crest upgraded the stock to “Overweight” rating in Thursday, January 12 report. The stock of Globant S.A. (NYSE:GLOB) has “Overweight” rating given on Thursday, August 11 by JP Morgan. The stock has “Buy” rating by Cowen & Co on Friday, January 26. See Globant S.A. (NYSE:GLOB) latest ratings:

26/01/2018 Broker: Cowen & Co Rating: Buy New Target: $55.0 Maintain
16/11/2017 Broker: SunTrust Rating: Hold New Target: $45.0 Maintain
17/11/2017 Broker: Cantor Fitzgerald Rating: Neutral Old Target: $42 New Target: $36 Maintain
20/10/2017 Broker: SunTrust Rating: Hold New Target: $48.0 Maintain
12/10/2017 Broker: Cowen & Co Rating: Buy New Target: $50.0 Maintain
28/09/2017 Broker: KeyBanc Capital Markets Rating: Hold Maintain

Analysts expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report $-0.58 EPS on March, 15.They anticipate $0.07 EPS change or 10.77% from last quarter’s $-0.65 EPS. After having $-0.65 EPS previously, Karyopharm Therapeutics Inc.’s analysts see -10.77% EPS growth. The stock increased 0.33% or $0.05 during the last trading session, reaching $15.03. About 13,503 shares traded. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 21.19% since February 20, 2017 and is uptrending. It has outperformed by 4.49% the S&P500.

The stock increased 0.10% or $0.05 during the last trading session, reaching $51.44. About 33,059 shares traded. Globant S.A. (NYSE:GLOB) has risen 4.32% since February 20, 2017 and is uptrending. It has underperformed by 12.38% the S&P500.

Globant S.A. develops and provides software solutions to clients in North America, the Latin America, Europe, and Asia. The company has market cap of $1.81 billion. It offers API management, e-commerce, and digital solutions; graphics engineering, game engineering, gaming experience, VR/AR development, and digital platform services; Big Data services, such as data integration, data architecture, scalable platform, blockchain, data visualization, and data science; testing center, test automation, mobile testing, and load and performance testing services. It has a 65.2 P/E ratio. The firm also provides enterprise consumerization services, including enterprise operations, collaboration solutions, cloud development, and talent management; UX design services comprising service, user experience, industrial design, and visual design; and native development, product development, and enterprise mobility services for mobiles.

Investors sentiment decreased to 1.02 in 2017 Q3. Its down 0.04, from 1.06 in 2017Q2. It turned negative, as 20 investors sold Globant S.A. shares while 27 reduced holdings. 23 funds opened positions while 25 raised stakes. 22.09 million shares or 4.19% less from 23.06 million shares in 2017Q2 were reported. Cap World Investors has invested 0.03% in Globant S.A. (NYSE:GLOB). Denver Investment Advsrs Lc has 10,283 shares for 0.02% of their portfolio. Millennium Ltd Llc invested 0.01% in Globant S.A. (NYSE:GLOB). Raymond James And Associate, Florida-based fund reported 8,844 shares. Vanguard Gru Inc has 0% invested in Globant S.A. (NYSE:GLOB) for 6,528 shares. Parametric Assocs Llc reported 0% of its portfolio in Globant S.A. (NYSE:GLOB). Sloane Robinson Limited Liability Partnership has invested 8.02% in Globant S.A. (NYSE:GLOB). Jpmorgan Chase And Com accumulated 2.31 million shares or 0.02% of the stock. Rwc Asset Mngmt Ltd Liability Partnership, a United Kingdom-based fund reported 431,416 shares. Us Financial Bank De holds 10,554 shares or 0% of its portfolio. Tompkins Financial Corporation holds 0.01% or 671 shares in its portfolio. Stephens Invest Mgmt Group Limited Liability Com reported 235,287 shares stake. Invesco Ltd, Georgia-based fund reported 359,498 shares. Global X Llc holds 106,813 shares or 0.12% of its portfolio. Bnp Paribas Arbitrage has invested 0% of its portfolio in Globant S.A. (NYSE:GLOB).

Since August 29, 2017, it had 0 insider purchases, and 17 sales for $1.27 million activity. Kauffman Michael also sold $100,882 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares. Primiano Christopher Brett sold $21,950 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Tuesday, August 29. Mirza Mansoor Raza sold $19,500 worth of stock. $125,048 worth of stock was sold by Shacham Sharon on Wednesday, February 7.

Investors sentiment increased to 2.5 in Q3 2017. Its up 0.94, from 1.56 in 2017Q2. It increased, as 5 investors sold Karyopharm Therapeutics Inc. shares while 11 reduced holdings. 7 funds opened positions while 33 raised stakes. 27.91 million shares or 3.47% more from 26.98 million shares in 2017Q2 were reported. 7,157 were reported by Barclays Public Ltd Company. Amer Interest Grp owns 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 22,659 shares. State Of Wisconsin Investment Board stated it has 26,000 shares. The Massachusetts-based Geode Mngmt Lc has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Bankshares Of America Corp De, North Carolina-based fund reported 46,400 shares. Deutsche Bankshares Ag invested in 0% or 162,265 shares. Virtu Limited Liability reported 18,293 shares. Citadel Advsrs Ltd accumulated 20,030 shares. New York-based Opus Point Ltd has invested 0.99% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Moreover, Jpmorgan Chase has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Wellington Mngmt Gru Ltd Liability Partnership owns 6.29 million shares. Moreover, Metropolitan Life Insurance Com New York has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 21,911 shares. Jacobs Levy Equity Management owns 24,600 shares. D E Shaw And Incorporated invested in 60,549 shares or 0% of the stock. Fmr Ltd Liability Corporation accumulated 4.01 million shares.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>